Company intelligence / Profile preview

Spindiag

Freiburg im Breisgau, Baden-Württemberg, Germany

Ownership: Private
Employees: ~59
Development stage: Other

Overview

Developed CE-IVD approved PCR rapid tests for SARS-CoV-2 and multidrug-resistant bacteria; launched SARS-CoV-2 test in November 2020. Filed for insolvency proceedings under self-administration on June 21, 2023; status unclear as of May 2025.

Therapeutic areas: Infectious Diseases
Industry: Molecular Diagnostics

Partnerships

Hahn-Schickard InstituteUniversity of Freiburg Medical CenterKlinikum Stuttgart

Beyond the preview

Go deeper on Spindiag.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spindiag.

Explore the full profile